Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia

Trial Profile

Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Raloxifene (Primary)
  • Indications Schizophrenia and disorders with psychotic features
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 07 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 22 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top